<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.8" -->
<?xml-stylesheet href="https://www.psychdb.com/lib/exe/css.php?s=feed" type="text/css"?>
<rdf:RDF
    xmlns="http://purl.org/rss/1.0/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
    xmlns:dc="http://purl.org/dc/elements/1.1/">
    <channel rdf:about="https://www.psychdb.com/feed.php">
        <title>PsychDB meds</title>
        <description></description>
        <link>https://www.psychdb.com/</link>
        <image rdf:resource="https://www.psychdb.com/lib/tpl/bootstrap3/images/favicon.ico" />
       <dc:date>2026-07-18T01:17:51-0700</dc:date>
        <items>
            <rdf:Seq>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/1-prescribing?rev=1621562117&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/agitation?rev=1643155896&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/alpha-1-antagonist-blocker?rev=1588309912&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/cytochrome-p450?rev=1712037063&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/inpatient-prn-overuse?rev=1588309912&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/measurement-based-care?rev=1762137246&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/paradoxical-reactions?rev=1599636633&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/pharmacogenetics?rev=1736821067&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/plasma-levels?rev=1644442883&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/qtc?rev=1762309505&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/tachyphylaxis?rev=1603241002&amp;do=diff"/>
                <rdf:li rdf:resource="https://www.psychdb.com/meds/urine-drug-screen?rev=1649362510&amp;do=diff"/>
            </rdf:Seq>
        </items>
    </channel>
    <image rdf:about="https://www.psychdb.com/lib/tpl/bootstrap3/images/favicon.ico">
        <title>PsychDB</title>
        <link>https://www.psychdb.com/</link>
        <url>https://www.psychdb.com/lib/tpl/bootstrap3/images/favicon.ico</url>
    </image>
    <item rdf:about="https://www.psychdb.com/meds/1-prescribing?rev=1621562117&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2021-05-20T18:55:17-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>Introduction to Prescribing Medication</title>
        <link>https://www.psychdb.com/meds/1-prescribing?rev=1621562117&amp;do=diff</link>
        <description>Introduction to Prescribing Medication

Primer

Medication prescription is cornerstone of psychiatric practice, and indeed for many areas and specialties of medicine. Understanding principles of prescribing and being a thoughtful and careful prescriber is critically important.</description>
    </item>
    <item rdf:about="https://www.psychdb.com/meds/agitation?rev=1643155896&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2022-01-25T16:11:36-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>Pharmacological Management of Acute Behavioural Agitation</title>
        <link>https://www.psychdb.com/meds/agitation?rev=1643155896&amp;do=diff</link>
        <description>Pharmacological Management of Acute Behavioural Agitation

Primer

Acute agitation (a “Code White”) in the medical setting can present as a challenge for both patients and health care providers. When using medications to manage acute agitation, there are several key concepts to consider, including the route of administration, onset of action, absorption, half-life, and the risk of adverse events.</description>
    </item>
    <item rdf:about="https://www.psychdb.com/meds/alpha-1-antagonist-blocker?rev=1588309912&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2020-04-30T22:11:52-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>Alpha-1 Blockers</title>
        <link>https://www.psychdb.com/meds/alpha-1-antagonist-blocker?rev=1588309912&amp;do=diff</link>
        <description>Alpha-1 Blockers</description>
    </item>
    <item rdf:about="https://www.psychdb.com/meds/cytochrome-p450?rev=1712037063&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2024-04-01T22:51:03-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>Cytochrome (CYP) P450 Metabolism</title>
        <link>https://www.psychdb.com/meds/cytochrome-p450?rev=1712037063&amp;do=diff</link>
        <description>Cytochrome (CYP) P450 Metabolism



Primer

The Cytochrome P450 System (CYP) is a family of heme-containing mono-oxygenases enzymes that detoxify foreign compounds (i.e. - medications and drugs) in the liver. Cytochrome P450 enzymes are responsible for most phase I reactions in the liver. Understanding the role of CYP enzymes is vital in the prescribing of psychotropic medications.</description>
    </item>
    <item rdf:about="https://www.psychdb.com/meds/inpatient-prn-overuse?rev=1588309912&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2020-04-30T22:11:52-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>Inpatient PRN Overuse</title>
        <link>https://www.psychdb.com/meds/inpatient-prn-overuse?rev=1588309912&amp;do=diff</link>
        <description>Inpatient PRN Overuse

Primer

PRNs (from the Latin pro re nata: for an occasion that has arisen) are a typical prescribing practice in most in-patient psychiatric units. There is limited evidence for the clinical effectiveness of as needed medications.</description>
    </item>
    <item rdf:about="https://www.psychdb.com/meds/measurement-based-care?rev=1762137246&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2025-11-02T18:34:06-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>Measurement-Based Care (MBC)</title>
        <link>https://www.psychdb.com/meds/measurement-based-care?rev=1762137246&amp;do=diff</link>
        <description>Measurement-Based Care (MBC)

Primer

	*  Substack: Thomas Insel: Measures That Matter
	*  Fortney, J. C., Unützer, J., Wrenn, G., Pyne, J. M., Smith, G. R., Schoenbaum, M., &amp; Harbin, H. T. (2016). A tipping point for measurement-based care. Psychiatric Services, 68(2), 179-188.
	*  Guo, T., Xiang, Y. T., Xiao, L., Hu, C. Q., Chiu, H. F., Ungvari, G. S., ... &amp; Feng, Y. (2015). Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. Ameri…</description>
    </item>
    <item rdf:about="https://www.psychdb.com/meds/paradoxical-reactions?rev=1599636633&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2020-09-09T00:30:33-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>Paradoxical Reactions</title>
        <link>https://www.psychdb.com/meds/paradoxical-reactions?rev=1599636633&amp;do=diff</link>
        <description>Paradoxical Reactions

Primer

Paradoxical Reactions are an unintended, paradoxical response to a medication. In the case of benzodiazepines, it can result in excessive movements, agitation, talkativeness, impulsivity, irritability, and/or excitement (the opposite of a benzodiazepine's intended effect). The incidence of paradoxical reactions are rare, at less than 1%. However, the</description>
    </item>
    <item rdf:about="https://www.psychdb.com/meds/pharmacogenetics?rev=1736821067&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2025-01-13T18:17:47-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>Pharmacogenetic Testing</title>
        <link>https://www.psychdb.com/meds/pharmacogenetics?rev=1736821067&amp;do=diff</link>
        <description>Pharmacogenetic Testing

Primer

Pharmacogenetics is the study of inherited genetic differences in drug metabolic pathways which can affect individual responses to drugs, both in terms of therapeutic effect as well as adverse effects. There is increasing interest in trying to use pharmacogenetics to understand which patients will respond best to which psychotropic medications.</description>
    </item>
    <item rdf:about="https://www.psychdb.com/meds/plasma-levels?rev=1644442883&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2022-02-09T13:41:23-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>Drug Plasma Levels</title>
        <link>https://www.psychdb.com/meds/plasma-levels?rev=1644442883&amp;do=diff</link>
        <description>Drug Plasma Levels

Primer

Drug Plasma Levels may be helpful to determine if a patient is adherent to medication, or has the appropriate  serum levels of medications for a response.

Tips

	*  First of all, consider is there a clinically useful assay to measure this drug?</description>
    </item>
    <item rdf:about="https://www.psychdb.com/meds/qtc?rev=1762309505&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2025-11-04T18:25:05-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>QT (QTc) Prolongation and Monitoring</title>
        <link>https://www.psychdb.com/meds/qtc?rev=1762309505&amp;do=diff</link>
        <description>QT (QTc) Prolongation and Monitoring

Primer

QT (QTc) Prolongation is associated with many psychotropic medications (especially antipsychotics) and some are linked to serious ventricular arrhythmias (e.g. - Torsades de Pointes) and sudden cardiac death. The risk of QT prolongation is likely dose-related, but the overall absolute risk is low. ECG monitoring is recommended for all patients on QT-prolonging agents, especially those taking medications long-term. There are few guidelines on the moni…</description>
    </item>
    <item rdf:about="https://www.psychdb.com/meds/tachyphylaxis?rev=1603241002&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2020-10-20T17:43:22-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>Tachyphylaxis</title>
        <link>https://www.psychdb.com/meds/tachyphylaxis?rev=1603241002&amp;do=diff</link>
        <description>Tachyphylaxis

Primer

Tachyphylaxis is the continued or repeated exposure to a drug that may lead to a weakened pharmacological response. This thought to be due to diminished receptor sensitivity in response to the persistent stimulation by an agonist drug, which produces a diminished pharmacological response.</description>
    </item>
    <item rdf:about="https://www.psychdb.com/meds/urine-drug-screen?rev=1649362510&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2022-04-07T13:15:10-0700</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>Urine Drug Screen</title>
        <link>https://www.psychdb.com/meds/urine-drug-screen?rev=1649362510&amp;do=diff</link>
        <description>Urine Drug Screen

Primer

The Urine Drug Screen (UDS) has several limitations, including only testing for a limited for a number of drugs, plus false positives/negatives are common. There can be a lack of temporal correlation with the UDS result and the clinical presentation. Urine drug screens at one hospital are also not always the same at another site.</description>
    </item>
</rdf:RDF>
